多西紫杉醇同步加量调强放疗在晚期NSCLC患者中的应用效果分析  

Analysis on theApplication Effect of Docetaxel Plus Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Patients with Advanced NSCLC

作　　者：刘维鹏 冯连杰[1] 朱青山[1] 赵世杰[1] 魏涛[1] LIU Weipeng;FENG Lianjie;ZHU Qingshan;ZHAO Shijie;WEI Tao(The Third Department of Radiotherapy,Anyang Cancer Hospital,Anyang 455000,China)

机构地区：[1]安阳市肿瘤医院放疗三科,河南安阳455000

出　　处：《临床医学工程》2021年第6期757-758,共2页Clinical Medicine & Engineering

摘　　要：目的探讨多西紫杉醇同步加量调强放疗在晚期非小细胞肺癌(NSCLC)患者中的应用效果。方法选取2018年6月至2019年8月我院收治的晚期NSCLC患者35例,随机分为两组。对照组给予多西紫杉醇和地塞米松治疗,观察组在对照组基础上给予同步加量调强放疗治疗。比较两组的临床疗效、Cyfra21-1水平、健康状况。结果观察组的总缓解率显著高于对照组(P<0.05)。治疗24周后,两组的血清Cyfra21-1水平均显著降低,且观察组显著低于对照组(P<0.05)。治疗24周后,两组的功能状态量表(KPS)评分均显著提高,且观察组显著高于对照组(P<0.05)。结论多西紫杉醇同步加量调强放疗治疗晚期NSCLC的效果显著,可有效降低患者的血清Cyfra21-1水平,改善患者健康状况。Objective To explore the application effect of docetaxel plus simultaneous integrated boost intensity modulated radiotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods 35 patients with advanced NSCLC admitted to our hospital from June 2018 to August 2019 were selected and randomly divided into two groups.The control group was treated with docetaxel and dexamethasone,and the observation group was treated with simultaneous integrated boost intensity modulated radiotherapy on the basis of control group.The clinical efficacy,Cyfra21-1 level and health status were compared between two groups.Results The total remission rate of observation group was significantly higher than that of control group(P<0.05).After 24 weeks of treatment,both groups had significantly decreased serum Cyfra21-1 level,and the observation group was significantly lower than the control group(P<0.05).After 24 weeks of treatment,both groups had significantly increased functional status scale(KPS)score,and the observation group was significantly higher than the control group(P<0.05).Conclusions Docetaxel plus simultaneous integrated boost intensity modulated radiotherapy in the treatment of advanced NSCLC has significant effect,and can effectively reduce the serum Cyfra21-1 level and improve the health status of patients.

关 键 词：晚期非小细胞肺癌 多西紫杉醇 同步加量调强放疗 

分 类 号：R734.2[医药卫生—肿瘤]